Assisted reproduction is a popular track that has received more attention in the recent past, but many stockholders do not know what are the conceptual stocks of assisted reproduction, and today the financial junta has compiled a list of leading stocks of assisted reproduction concept for stockholders' friends for your reference.
Changchun Hi-Tech (000661)
Changchun Hi-Tech (000661) Technology Industry (Group) Co. The main products of the company are Polyethylene Glycol Recombinant Human Growth Hormone Injection, Recombinant Human Growth Hormone, Recombinant Human Follicle Promoting Hormone for Injection, Lyophilized Varicella Attenuated Vaccine, Human Rabies Vaccine, Thrombophilus Cardiac Arteriosclerosis Tablets, and Ginkgo Biloba Urinary Inflammation Tablets.
Tongze Medical (600763)
Tongze Medical (600763) Co. The company's main products are medical services. The company is the vice chairman of Zhejiang Health Industry Federation, won the top 50 most competitive listed companies in China's pharmaceutical (600056), was selected as one of Forbes China's top 100 most promising listed companies for five consecutive years, and has been listed on the Zhonglian Listed Companies 100 list for many times, and was included in the MSCI China A-share Onshore Index in August 2018, and was ranked in the value of listed companies list of the 2019 China Capital Annual Meeting Ranked 18th in TOP100, awarded "Golden Quality - Most Growing Enterprise Award" by Shanghai Securities News in 2019 for listed companies, listed in Forbes 2019 Asia Top 200 Small and Medium-sized Listed Enterprises List, and awarded by Deloitte and Harvard Business Review for two consecutive years in 2019 and 2020. Awarded BMC "China's Excellent Management Company" by Deloitte and Harvard Business Review, etc., listed as one of Hurun China's Top 500 Private Enterprises in 2020, and awarded the "[Golden Intelligence Award]" by the financial sector...
Dian Diagnostics (300244)
Dian Diagnostics (300244) Technology Group Company Limited's main business is medical diagnostic services and in vitro diagnostic products sales. The company's main products and services are diagnostic services, diagnostic products, cold chain logistics, health checkups, and financial leasing. In terms of oncology discipline, the company continues to deepen the discipline construction and marketing force building in parallel, in September in the CSCO Academic Annual Meeting won the second place in the CSCO annual meeting of the best satellite meeting (genetic testing group). We have obtained three Class III registration certificates, one Class II registration certificate, 27 Class I filed products, and one Class III diagnostic product is currently in the registration process.
Guang Shengtang (300436)
Fujian Guangshengtang (300436) Pharmaceutical Co., Ltd.'s main business is the research and development, production and sales of nucleoside anti-hepatitis B virus drugs; the company's main products are anti-hepatitis B virus drugs, hepatoprotective and liver-protecting drugs, drugs for the digestive system, respiratory system drugs, cardiovascular The company's main products are anti-hepatitis B virus drugs, hepatoprotective drugs, digestive system drugs, respiratory system drugs, cardiovascular drugs, and medical testing services; the company is currently a domestic pharmaceutical enterprise focusing on the field of liver health, and it is the only pharmaceutical enterprise in China that owns four major clinically preferred anti-hepatitis B virus drugs, namely, adefovir, lamivudine, entecavir, and tenofovir, simultaneously.
Lizhu Group (000513)
Lizhu Pharmaceutical Group Co., Ltd. is mainly engaged in the research and development, production and sales of pharmaceutical products, with the main products covering preparations, APIs and intermediates, and diagnostic reagents and equipment, and the main products include One-Li'an (epprazole enteric-coated tablets and epprazole sodium for injection), Lizhu The main products include One Lian (Epprazole Enteric Tablets and Epprazole Sodium for Injection), Lizhu Deluxe (Bismuth Potassium Citrate) series products, Beyi (Leuprolide Acetate Microspheres for Injection), Lishenbao (Urolysin for Injection), Lebold (Urolysin for Injection), Ginseng Astragali Fuzheng Injection, Antiviral Pellet, Lifuokang (Voriconazole for Injection), and Likangluo (Murine Nerve Growth Factor for Injection) and other preparations, as well as API and intermediates, such as Mevastatin, Acarbose, Mucins Sulfate, Phenylalanine, Ceftriaxone Sodium and other APIs. The company also produces diagnostic reagents such as HIV antibody diagnostic reagents, Mycoplasma pneumoniae antibody diagnostic reagents and syphilis antibody diagnostic reagents.
Fosun Pharmaceuticals (600196)
Shanghai Fosun Pharmaceuticals (600196) (Group) Company Limited is mainly engaged in the business of pharmaceuticals, medical devices and medical diagnostics, and healthcare services. The main products are core products in the field of treatment of cardiovascular system diseases, core products in the field of treatment of central nervous system diseases, core products in the field of treatment of blood system diseases, core products in the field of treatment of metabolic and digestive system diseases, core products in the field of treatment of anti-infective diseases, core products in the field of treatment of antitumor, core products in the field of APIs and intermediates. According to the 2018 list of the top 100 enterprises in China's pharmaceutical industry issued by the China Pharmaceutical Industry Information Center of the Ministry of Industry and Information Technology of the People's Republic of China*** and the State of China, the Group was ranked No. 7; according to the IQVIA statistics, in 2019, the Group ranked No. 10 in the country in terms of sales revenue from the hospital-use prescription drugs manufactured by the Group.As one of the largest enterprises in the world in the production, research and development, and manufacturing of anti-malarial medicines, the Group has become a global fund, United Nations Children's Fund, the World Health Organization and the drug procurement centers of African countries...
Minova (603538)
Ningbo Minova (603538) Pharmaceutical Co., Ltd. is mainly engaged in the research and development, production and sales of specialty APIs (including intermediates) and finished products, whose main categories include cardiovascular and gastrointestinal drugs. The company's main products are valsartan, chloretin, perindopril, resuvastatin, atorvastatin, clopidogrel and esomeprazole, ticlopidine, duloxetine and mirtazapine. The company's important API production bases are all national high-tech enterprises, and all of them have established strict quality management system, EHS management system, and passed the GMP certification of the European Union, China, Japan and other regulated markets. The company is one of China's top 100 pharmaceutical internationalization enterprises, quality suppliers and partners in the international market (ranked in the top 60), core products covering cardiovascular, central nervous system, gastrointestinal and digestive tract and other therapeutic areas, and is one of the domestic exporters of the most varieties of speciality APIs to Europe.
Hanshang Group (600774)
Hanshang Group (600774) Co., Ltd. is engaged in the main business is the pharmaceutical business, medical equipment business, commercial operations business, exhibition operations business, the business model is joint venture + leasing + brand agency. The Group has been on the list of top 100 provincial and municipal enterprises for several consecutive years, and has been awarded the title of "The Most Growing Listed Company in New Retail Industry" on the IWOM list of listed companies in China, and has realized the thirty-first year of safety without accidents. After the completion of the major asset purchase, the company will be in the original commercial sector business based on the further introduction of high-quality pharmaceutical manufacturing sector subject assets.
Sai Sheng Pharmaceuticals (300485)
Beijing Sai Sheng Pharmaceuticals (300485) Co., Ltd.'s main business for the research and development of injectable injections, production and sales, the leading products for the biological and biochemical pharmaceuticals, related to cardiovascular and cerebrovascular diseases, immune diseases (anti-tumor) and neurological diseases in three major areas of medication. The company is the original drafting unit of national drug standard for 5 varieties of fibrinolytic enzyme, fibrinolytic enzyme injection, fibrinolytic enzyme for injection, Ganoderma lucidum peptide injection and sodium deoxyribonucleotide injection; fibrinolytic enzyme injection, Ganoderma lucidum peptide injection, sodium deoxyribonucleotide injection and 100mg thymopeptide for injection are the first ones produced in the country; tetrahexylsalicylate ganglioside sodium injection (GM-1) and Ganoderma lucidum peptide injection are the national key new products; and Ganoderma lucidum peptide injection is the national key new product; and Ganoderma lucidum peptide injection is the national key new product. Fibrinolytic enzyme, Fibrinolytic enzyme injection, Fibrinolytic enzyme for injection, Thymopeptide for injection in large size were awarded as Beijing independent innovation products; Immunoaffinity chromatography scale purification of Fibrinolytic enzyme isolation and its pharmacological properties, the development of pharmaceutical preparations won the Beijing Science and Technology...
Huada Genetics (300676)
Shenzhen Huada Genetics (300676) Co., Ltd.'s main business is to provide research services and comprehensive solutions of precision medical testing for scientific research institutes, enterprises and public institutions, medical institutions, and social hygiene organizations by means of multi-organism big data technology such as genetic testing, mass spectrometry testing, and bioinformatics analysis. We provide research services and comprehensive solutions for precision medical testing for scientific research organizations, enterprises, institutions, medical institutions and social health organizations. The company's main products include pregnancy nutrition testing, human amino acid testing, human vitamin testing, etc. The company has been awarded the "2019 Annual Nutritional Testing Award". The Company has won the "2019 China's Most Respected Enterprise", "Value Partner Award", "Golden Bull Award. 2018 Investor Relations Management Award", "China Securities Golden Bauhinia Award. Best IR Team", "The First A-Share Technology Leading 50 Carnival. Best Investor Service Award", "Global CSR Health Promotion Award", "China Poverty Alleviation and Development Association Outstanding Member Unit in Poverty Alleviation", "2018 Outstanding Public Welfare Project Award" (Cervical Cancer Prevention and Control Special) and many other honors, effectively enhancing the company's influence and beauty...